Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies, Multiple Sclerosis Journal, November 2019, SAGE Publications,
DOI: 10.1177/1352458519888610.
You can read the full text:

Read

Contributors

The following have contributed to this page